Isoliquiritigenin - CAS 961-29-5
Catalog number: 961-29-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C15H12O4
Molecular Weight:
256.25
COA:
Inquire
Targets:
Aldose Reductase
Description:
Isoliquiritigenin, an anti-tumor flavonoid from the root of Glycyrrhiza glabra, inhibiting aldose reductase with an IC50 of 320 nM.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Isoliquiritigenin Attenuates Adipose Tissue Inflammation in vitro and Adipose Tissue Fibrosis through Inhibition of Innate Immune Responses in Mice.
Watanabe Y1, Nagai Y1,2, Honda H1,3, Okamoto N1, Yamamoto S4, Hamashima T4, Ishii Y4, Tanaka M5, Suganami T2,5, Sasahara M4, Miyake K6,7, Takatsu K1,3. Sci Rep. 2016 Mar 15;6:23097. doi: 10.1038/srep23097.
Isoliquiritigenin (ILG) is a flavonoid derived from Glycyrrhiza uralensis and potently suppresses NLRP3 inflammasome activation resulting in the improvement of diet-induced adipose tissue inflammation. However, whether ILG affects other pathways besides the inflammasome in adipose tissue inflammation is unknown. We here show that ILG suppresses adipose tissue inflammation by affecting the paracrine loop containing saturated fatty acids and TNF-α by using a co-culture composed of adipocytes and macrophages. ILG suppressed inflammatory changes induced by the co-culture through inhibition of NF-κB activation. This effect was independent of either inhibition of inflammasome activation or activation of peroxisome proliferator-activated receptor-γ. Moreover, ILG suppressed TNF-α-induced activation of adipocytes, coincident with inhibition of IκBα phosphorylation. Additionally, TNF-α-mediated inhibition of Akt phosphorylation under insulin signaling was alleviated by ILG in adipocytes.
2.Isoliquiritigenin ameliorates dextran sulfate sodium-induced colitis through the inhibition of MAPK pathway.
Choi YH1, Bae JK1, Chae HS1, Choi YO1, Nhoek P1, Choi JS2, Chin YW3. Int Immunopharmacol. 2016 Feb;31:223-32. doi: 10.1016/j.intimp.2015.12.024. Epub 2016 Jan 7.
Isoliquiritigenin (isoLQ), a chalcone found in licorice, has shown a variety of biological activity including anti-inflammatory and antioxidative effects, and the distribution of isoLQ in gastrointestinal tract was higher than any other tissues. Thus, we evaluated whether or not isoLQ attenuated the dextran sulfate sodium (DSS)-induced colitis by observing the physiological changes (body weight loss, diarrhea, bleeding stool, overall disease activity index (DAI) scores, colon length), histopathological analysis and myeloperoxidase (MPO) activities of esophagus and colon. Also, the MAPK pathways including phosphorylation of ERK1/2, p38, and AKT, and the activation of NK-κB were evaluated in colon tissue. Interestingly, the reduction of body weight and colon length, increase of diarrhea, bloody stool, DAI scores and MPO activity, and histologic disturbances in DSS-induced colitis were recovered by isoLQ treatment. Also, isoLQ treatment suppressed the phosphorylation of ERK1/2 and p38, and the activation of NK-κB compared to those in DSS-induced colitis mice.
3.Isoliquiritigenin Inhibits Proliferation and Induces Apoptosis via Alleviating Hypoxia and Reducing Glycolysis in Mouse Melanoma B16F10 Cells.
Wang Y, Ma J, Yan X, Chen X, Si L, Liu Y, Han J, Hao W, Zheng Q1. Recent Pat Anticancer Drug Discov. 2016;11(2):215-27.
BACKGROUND: Isoliquiritigenin (ISL) is a licorice chalcone. According to CN104758274, CN101658513 and US009089546, it is claimed that ISL has anti-inflammatory, anti-oxidative, and anti-tumoral effects.
4.Anti-osteoclastogenic activity of isoliquiritigenin via inhibition of NF-κB-dependent autophagic pathway.
Liu S1, Zhu L1, Zhang J1, Yu J1, Cheng X1, Peng B2. Biochem Pharmacol. 2016 Apr 15;106:82-93. doi: 10.1016/j.bcp.2016.03.002. Epub 2016 Mar 3.
Previous studies, including those from our laboratory, have demonstrated that the natural flavonoid isoliquiritigenin (ISL) is a promising agent for bone destructive diseases. However, the mechanisms underlying its anti-osteoclastogenic effects are still far from clear. Here, we evaluated the potential alterations of autophagy and nuclear factor-κB (NF-κB) during anti-osteoclastogenic effects by ISL in vitro and in vivo. We observed that ISL inhibited the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and suppressed autophagic microtubule-associated protein light chain 3 (LC3)-II and Beclin 1 accumulation. ISL treatment resulted in the interruption of several specific features for autophagy in osteoclast precursors, including acidic vesicular organelle formation, LC3-II accumulation, and appearance of autophagic vacuoles. The RANKL-stimulated expression levels of autophagy-related genes and proteins also diminished in ISL-treated osteoclast precursors.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Aldose Reductase Products


CAS 110703-94-1 Zopolrestat

Zopolrestat
(CAS: 110703-94-1)

Zopolrestat is an inhibitor of Aldose Reductase(AR). It has been shown to play roles in inflammation and cancer. It is used for the treatment of diabetic nephro...

CAS 82964-04-3 Tolrestat

Tolrestat
(CAS: 82964-04-3)

Tolrestat is an orally active and potent aldose reductase inhibitor with IC50 value of 35 nM. It was approved for the control of certain diabetic complications....

Aldose reductase-IN-1
(CAS: 1355612-71-3)

Aldose reductase-IN-1, an aldose reductase inhibitor, could have potential biological usage in the study of breast cancer. IC50: 28.9 pM.

CAS 105346-34-7 FR-62765

FR-62765
(CAS: 105346-34-7)

FR-62765, a derivative of WF-3681, is a novel aldose reductase inhibitor. It might be a useful drug for diabetic neuropathy.

CAS 147254-64-6 Raniestat

Raniestat
(CAS: 147254-64-6)

Raniestat, a highly potent aldose reductase inhibitor currently under phase III clinical trials in the US and Canada, is used to treat diabetic neuropathies.

CAS 82159-09-9 Epalrestat

Epalrestat
(CAS: 82159-09-9)

Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM.

CAS 51876-97-2 Alrestatin (sodium)

Alrestatin (sodium)
(CAS: 51876-97-2)

Alrestatin sodium is a specific inhibitor of aldose reductase (IC50 = 148 μM).

CAS 72702-95-5 Ponalrestat

Ponalrestat
(CAS: 72702-95-5)

Ponalrestatis an aldose reductase inhibitor originator byAstraZeneca. It can block the conversion of glucose to sorbitol. Ponalrestatis shows selectivity for al...

CAS 4450-98-0 EBPC

EBPC
(CAS: 4450-98-0)

EBPC is a potent and selective aldose reductase inhibitor. It is used to improve the cytotoxicity of anticancer reagents such as cisplatin and doxorubicin in He...

CAS 961-29-5 Isoliquiritigenin

Isoliquiritigenin
(CAS: 961-29-5)

Isoliquiritigenin, an anti-tumor flavonoid from the root of Glycyrrhiza glabra, inhibiting aldose reductase with an IC50 of 320 nM.

CAS 51411-04-2 Alrestatin

Alrestatin
(CAS: 51411-04-2)

Alrestatin is an inhibitor of aldose reductase (IC50 = 148 μM).

CAS 112733-06-9 Zenarestat

Zenarestat
(CAS: 112733-06-9)

Zenarestat is an aldose reductase inhibitor. It was investigated as a treatment of diabetic neuropathy and cataract. It was developed by Fujisawa Pharmaceutical...

Chemical Structure

CAS 961-29-5 Isoliquiritigenin

Quick Inquiry

Verification code

Featured Items